- 1、本文档共129页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* 在双重抗血小板加抗凝治疗的时代, GPIIb/IIIa拮抗剂不作为常规治疗。在一些血栓负荷重或没有足够噻氯吡啶类药物负荷的病人可能更有益。 * * * * * 结果是否能外推至STEMI不清楚。 * * * * * * * 比伐卢定:有抗因子II活性的抗凝剂,为直接凝血酶抑制剂 * 比伐卢定:有抗因子II活性的抗凝剂,为直接凝血酶抑制剂 * OASIS-6研究发现,PCI亚组中接受Fondaparinux的STEMI患者30天的死亡率和再梗死发生率增加1%。 * * * 普拉格雷比氯吡格雷的抗血小板作用更强。 Patients were candidates for the trial if they were moderate-high risk, had an acute coronary syndrome, and there was a plan to perform PCI. A sample size of 13, 600 was considered necessary to provide at least 90 % power to test the primary hypothesis All patients were to receive ASA. Randomization was stratified by UA/NSTEMI vs STEMI DB study drug therapy consisted either of - standard dosing with clopidogrel with a LD of 300 mg and MD of 75 mg - OR prasugrel with a LD of 60 mg and MD of 10 mg DB study drug was to be given for a median of at least 12 months with a minimum of 6 mos and maximum of 15 months The primary composite EP was CV death, MI, or Stroke through the end of the study Key secondary EPs are listed here and among these was Stent thrombosisKey safety Eps included: TIMI major (non CABG) bleeds, and life-threatening bleeds Two key substudies are evaluating pharmacokinetics and genomics * * * 在主要终点事件方面从第3天两组就开始有明显差异,并持续整个随访期。 This slide depicts the balance of efficacy and safety observed in the trial. At the top is shown the significant reduction in the primary endpoint as presented a few moments ago. The number needed to treat to prevent one event was 46 At the bottom is the rate of TIMI major non CABG bleeds--a key safety endpoint-- which was 2.4% with prasugrel and 1.8% with clopidogrel—a 0.6% Absolute risk increase. The excess of 35 major bleeds with prasugrel corresponded to an HR of 1.32 and P value of 0.03 . The number of subjects who would need to be treated to result in one excess major bleed (NNH) was 167. * * * The beneficial effect of prasugrel on the primary end point was consistent across key prespecified major subgroups. Notable observations include: A significant benefi
您可能关注的文档
- 2015.2糖尿病急性并发症识别、处理和预防__培训课件.ppt
- 2015版急性心肌梗死指南__培训课件.pptx
- 2016-3-29 3 降血糖药-胰岛素__培训课件.ppt
- 2016产科麻醉专家共识__培训课件.ppt
- 2016麻醉解剖学 脊柱区__培训课件.ppt
- 22164_胰岛素强化治疗的临床应用__培训课件.ppt
- ACS患者积极他汀治疗循证之路__培训课件.ppt
- ACS诊治流程__培训课件.ppt
- AMI与ACS临床路径__培训课件.ppt
- AMI再灌注治疗策略__培训课件.ppt
- 咨询工程师之工程项目组织与管理综合提升模拟题库附有答案详解.docx
- 2022-2023年注册工程师之专业知识练习试题提供答案解析.docx
- 2022-2023年一级建造师之一建建设工程经济考前冲刺练习试题附带答案.docx
- 2022-2023年二级建造师之二建机电工程实务练习题库附答案详解.docx
- 2023年咨询工程师之工程项目组织与管理测试卷附有答案详解.docx
- 2023年卫生招聘考试之卫生招聘(计算机信息管理)通关模拟考试试卷附有答案详解.docx
- 2022-2023年卫生招聘考试之卫生招聘(计算机信息管理)综合提升试卷提供答案解析.docx
- 集成功放TDA2030仿真测试.pdf
- 国际收支网上申报(企业版)操作手册.doc
- 湘潭大学2022下半年辅导员招聘试题.docx
文档评论(0)